CytomX Therapeutics (CTMX) Tops Q1 EPS by 25c

CytomX Therapeutics (NASDAQ: CTMX) reported Q1 EPS of $0.17, $0.25 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $41.46 million versus the consensus estimate of $19.92 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c